RaymondUOsarogiagbonMD

Physician

Overview of Dr. Osarogiagbon

Dr. Raymond Osarogiagbon is an oncologist in Memphis, TN and is affiliated with multiple hospitals in the area, including Baptist Memorial Hospital - Memphis, Baptist Memorial Hospital-Desoto, Baptist Memorial Hospital for Women, Baptist Memorial Hospital-Tipton, Methodist Le Bonheur Germantown Hospital, Saint Francis Hospital, Saint Francis Hospital-Bartlett, and Methodist Healthcare Memphis Hospitals. He received his medical degree from University of Ibadan and has been in practice 29 years. Dr. Osarogiagbon accepts several types of health insurance, listed below. He is one of 58 doctors at Baptist Memorial Hospital - Memphis and one of 31 doctors at Methodist Le Bonheur Germantown Hospital who specialize in Oncology. He has more than 100 publications and over 500 citings.

Office
80 Humphreys Center Dr
Ste 330
Memphis, TN 38120
Book by Phone+1(901) 660-2676

Fax+1 901-751-6170

Education & Training

University of MinnesotaFellowship, Hematology and Medical Oncology, 1995 - 1998
Texas Tech University (Amarillo)Residency, Internal Medicine, 1992 - 1995
University of IbadanClass of 1988

Certifications & Licensure

MS State Medical License 2005 - 2025
TN State Medical License 2004 - 2025
MN State Medical License 1995 - 2014
TX State Medical License 2000 - 2014
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Memphis Magazine: Top Doctors Castle Connolly, 2008-2014

Clinical Trials

Building a Multidisciplinary Bridge Across the Quality Chasm in Thoracic Oncology Start of enrollment: 2014 Oct 09
Completed
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Jul 08
Completed
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

Metrics for Benchmarking Lung Cancer Surgery Quality: Not Waiting for Godot!
Sora Ely, Raymond U Osarogiagbon
The Annals of Thoracic Surgery. 2025-02-01
Paradigm shift in early detection: Lung cancer screening to comprehensive CT screening.
James L Mulshine, Bruce Pyenson, Cheryl Healton, Carolyn Aldige, Riccardo S Avila
European Journal of Cancer. 2025-01-31
Barriers to Lung Cancer Screening in a Multi-Disciplinary Thoracic Oncology Program Cohort: Effects of an Incidental Pulmonary Nodule Program.
Wei Liao, Meredith A Ray, Anita Patel, Jessica Roma, Hope Marshall
Journal of Thoracic Oncology. 2025-01-30

Lectures

Prospective comparative effectiveness trial of multidisciplinary lung cancer (LC) care.
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

Lung Cancer Screening with LD Lung – Missed Opportunities for Early Lung Cancer DetectionSeptember 16th, 2024
Researchers: Lung Nodule Programs Can Catch Cancer EarlyMarch 10th, 2023
Baptist Cancer Center Research Proves Incidental Lung Nodule Program Effective in Detecting Cancer EarlyMarch 7th, 2023
Join now to see all

Insurance Accepted

Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
BCBS Tennessee Network 5
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Coventry Carelink Health Plans PPO
First Health PPO
Great West PPO
HIP of New York - Select PPO
Humana ChoiceCare Network PPO
Humana/ChoiceCare+ Network PPO
Multiplan PHCS PPO
Multiplan PPO
Qualchoice PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment